OncoMatch/Clinical Trials/NCT06682130
Glofitamab Bridging ASCT for Patients With Relapsed or Refractory DLBCL
Is NCT06682130 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Group A：Patients with PR or ctDNA positivity after salvage treatment and Group C: Patients with SD/PD after posterior treatment for diffuse large b-cell lymphoma(dlbcl).
Treatment: Group A：Patients with PR or ctDNA positivity after salvage treatment · Group C: Patients with SD/PD after posterior treatment — The objective of this study is to evaluate the efficacy and safety of the Glofitamab bridging ASCT regimen in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and to provide better clinical benefits to these patients.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Diffuse Large B-Cell Lymphoma
Non-Hodgkin Lymphoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: autologous hematopoietic stem cell transplantation
Lab requirements
Blood counts
Hemoglobin ≥ 9g/dL, Platelet count ≥ 70 × 10^9/L, The absolute value of neutrophils is ≥ 1.0 × 10^9/L, If accompanied by bone marrow invasion, platelet count ≥ 50 × 10^9/L, absolute neutrophil count ≥ 0.75 × 10^9/L, The number of CD34+cells is ≥ 2.0 × 10^9/kg
Kidney function
serum creatinine clearance rate ≥ 80 mL/min, creatinine <160 umol/l
Liver function
alanine aminotransferase and aspartate aminotransferase ≤ 2 times the upper limit of normal, total bilirubin <2 times the upper limit of normal
Cardiac function
ejection fraction ≥ 50%, asymptomatic arrhythmia
Cardiac function: ejection fraction ≥ 50%, asymptomatic arrhythmia; Liver function: alanine aminotransferase and aspartate aminotransferase ≤ 2 times the upper limit of normal, total bilirubin <2 times the upper limit of normal; Renal function: serum creatinine clearance rate ≥ 80 mL/min, creatinine <160 umol/l; Pulmonary function: Without oxygen inhalation, SPO2 >90%, FEV1, FVC, and DLCO ≥ 50% predicted values; Adequate bone marrow reserve is defined as: Hemoglobin ≥ 9g/dL, Platelet count ≥ 70 × 10^9/L, The absolute value of neutrophils is ≥ 1.0 × 10^9/L, If accompanied by bone marrow invasion, platelet count ≥ 50 × 10^9/L, absolute neutrophil count ≥ 0.75 × 10^9/L, The number of CD34+cells is ≥ 2.0 × 10^9/kg.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06682130 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior autologous hematopoietic stem cell transplantation disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 70 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify